Article Text

Download PDFPDF

359 Identifying predictors of survival for granulosa cell tumors of the ovary. A single institution retrospective study about 59 cases
  1. M Ghalleb1,
  2. O Jaidane1,
  3. H Rekik1,
  4. MA Bouida1,
  5. N Boujelbene2,
  6. M Hechiche1,
  7. R Chargui1 and
  8. K Rahal1
  1. 1Institute Salah Azaiez Of Oncology, Surgical Oncology, Tunis, Tunisia
  2. 2Institute Salah Azaiez Of Oncology, Pathology, Tunis, Tunisia


Objectives Granulosa cell tumor of the ovary (GCT) is a rare ovarian malignancy. The natural history of GCT is one of slow growth, with a tendency for late recurrence. However, in some cases it appears to be more aggressive. Our Aim is to identify prognostic factors for a better patient selection for adjuvant treatment.

Methods It’s a retrospective study about patients GCTs treated in our institution between january1993 to December 2014. Overall survival and disease free survival were defined according to NCI Dictionary of Cancer Terms.

Results A total of 59 women were included in this study. The median age was 55 year old (IQR 44–63). The mean tumor size was 14,92 ±7cm. 75,9% (n=35) were FIGO stage I. All our patients have been initially treated with surgery and the median follow up after surgery was 44 months (IQR 14–88). The overall survival (OS) at 5 and 10 years was respectively 92% and 82%. The disease free survival (DFS) at 5 and 10 years was 76,9% and 31,9%, respectively. In multivariate analysis, FIGO stage [aHR(95%CI): 3.67(1.1–11.9), P=0.03] and residual tumor [aHR(95%CI): 3.74(1.48–9.44) p=0.005] were independent risk factors for all-cause mortality. Similarly, after adjusting for potential confounders, FIGO stage was associated with a 70% decrease in DFS [aHR(95%CI): 1.77(1.04–3.01), P=0.034] whereas age increased DFS by 5% [aHR(95%CI): 0.95(0.91–0.98), P=0.012]

Conclusions In our study, we found non-modifiable prognostic factors that may help indicate adjuvant chemotherapy. Further studies in larger population, with longer follow-up to determine a clear threshold for adjuvant chemotherapy are warranted.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.